Kaiser Health News (KHN), a nonprofit health care news organization whose stories are widely and freely republished and rebroadcast, released an in-depth article and news video today about the 340B program and the fight over 340B contract pharmacy.
According to
…
Drug discount management company Kalderos sent email messages to 340B hospitals this week once again announcing the launch of its 340B Pay service to let drug companies pay 340B ceiling prices as back-end rebates instead of as front-end discounts on
…
The U.S. Health Resources Services Administration (HRSA) has ordered two drug manufacturers that it audited—Akorn Inc. and BioComp Pharma—to repay 340B covered entities for overcharges.
HRSA updated its fiscal year 2021 audit results on its website last week.
Bristol Myers Squibb’s Celgene subsidiary has removed purchasing limits due to demand-related supply constraints on its injectable acute myeloid leukemia (AML) drug Vidaza that have been in place since May 2020.
BMS announced the switch back to normal sales in
…
Drug manufacturer Janssen, a Johnson & Johnson company, has notified 340B covered entities they are or might be owed refunds for overcharges on 14 widely used products during the first and second quarters of 2021.
Janssen asked the U.S. Health
…
The decision by the U.S. Health Resources & Services Administration (HRSA) to refer six drug manufacturers to the U.S. Health and Human Services Department of the Office of The Inspector General (HHS OIG) for refusing to offer 340B discounts to
…
Hospital trade groups are lodging strong objections to maintaining steep cuts in Medicare Part B drug reimbursement as part of the Fiscal Year 2022 final rule for the hospital outpatient prospective payment system (OPPS), while the trade group for brand
…
The U.S. Health Resources & Services Administration (HRSA) today referred six drug manufacturers to the U.S. Health and Human Services Department of the Office of the Inspector General (HHS OIG) regarding their refusal to offer 340B discounts to 340B covered
…
Drug manufacturer Sanofi has sent letters to 340B covered entities that have complained to federal authorities about its denials of 340B pricing on drugs shipped to contract pharmacies, covered entity representatives say.
Sanofi has acknowledged but not responded to requests
…*Sign up for news summaries and alerts from 340B Report